logo
Plus   Neg
Share
Email

Supernus Pharma To Report Phase III SPN-812 Data - Your Attention, Please

supernus-dec06-lt.jpg

Supernus Pharmaceuticals Inc. (SUPN) is all set to report results from its two phase III studies of SPN-812 tomorrow, December 6, 2018, at approximately 7:00 a.m. ET.

SPN-812 is an investigational non-stimulant for the treatment of Attention-Deficit-Hyperactivity Disorder, or ADHD, under phase III development, which is believed to have a better side effect profile than other non-stimulant treatments for ADHD.

An estimated 6% to 9% of all school-age children and 3% to 5% of adults in the United States are reportedly affected by ADHD. About 25% of children with ADHD also exhibit persistent conduct problems, such as impulsive aggression, according to a report published in the Journal of the American Academy of Child and Adolescent Psychiatry.

The phase III program of SPN-812 consists of four three-arm, placebo-controlled trials namely, P301 and P303 trials in patients 6-11 years old, and P302 and P304 trials in patients 12-17 years old.

The results that are to be reported tomorrow are from the P301 and P303 trials in patients 6-11 years old.

Our detailed report on Supernus Pharma, alerting our premium subscribers to this stock, was first published on June 11, 2012, when it was trading around $5, and then again on August 26, 2013, when it was trading around $7.

SUPN closed Tuesday's (Dec.4, 2018) trading at $46.01, down 5.83%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT